Jazz Pharmaceuticals PLC
J7Z
Company Profile
Business description
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Contact
Waterloo Road
Fifth Floor, Waterloo Exchange
DublinD04 E5W7
IRLT: +353 16347800
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
2,890
Stocks News & Analysis
stocks
The 10 best US companies to invest in now
The stocks of these high-quality companies look cheap today.
stocks
Surge in combat drones drives upgrade for ASX share
Drone demand powers growth but investor optimism is overdone.
stocks
Meta: Meta launches enterprise offering to open up another way to monetize AI investments
The market’s negative reaction to the announcement signals that investors, much like us, are not super excited about Meta’s prospects in the enterprise market.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,854.70 | 60.30 | 0.69% |
| CAC 40 | 7,897.19 | 61.88 | 0.79% |
| DAX 40 | 25,231.20 | 291.85 | 1.17% |
| Dow JONES (US) | 51,176.96 | 250.40 | 0.49% |
| FTSE 100 | 10,461.95 | 33.68 | 0.32% |
| HKSE | 23,972.29 | 640.98 | -2.60% |
| NASDAQ | 27,190.86 | 319.27 | 1.19% |
| Nikkei 225 | 68,309.46 | 647.26 | -0.94% |
| NZX 50 Index | 13,680.49 | 130.02 | -0.94% |
| S&P 500 | 7,722.72 | 56.27 | 0.73% |
| S&P/ASX 200 | 8,682.10 | 67.70 | 0.79% |
| SSE Composite Index | 3,842.19 | 11.74 | 0.31% |